RecruitingNot ApplicableNCT06906640

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)

Sponsor

Duke University

Enrollment

420 participants

Start Date

Oct 28, 2025

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM

Summary

IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (Program 2 of IRIS-CKD) is testing whether a structured implementation program can improve treatment and management of people who already have both type 2 diabetes and chronic kidney disease (CKD), ensuring they receive all recommended therapies to slow kidney damage. **You may be eligible if...** - You are an adult with type 2 diabetes - You receive primary care within the participating healthcare system - Recent lab tests show significant kidney disease (high urine albumin or low kidney filtration rate) - You are not yet receiving all recommended kidney-protective medications **You may NOT be eligible if...** - You do not have confirmed CKD based on lab testing - You are already on all recommended guideline-directed therapies - You have contraindications to the recommended medications (such as high potassium levels or diabetic ketoacidosis) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHER(IRIS-CKD Management Program): Education

Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.

OTHER(IRIS-CKD Management Program): GDMT

Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.

Locations(6)

University of Alabama

Birmingham, Alabama, United States

Orlando Health

St. Petersburg, Florida, United States

University of Michigan

Ann Arbor, Michigan, United States

Essentia Institute of Rural Health

Duluth, Minnesota, United States

Duke University

Durham, North Carolina, United States

Baylor Scott & White

Temple, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06906640

Related Trials

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

NCT066138541 location

Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus

NCT068213993 locations

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

NCT0684520220 locations

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

NCT074652241 location

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

NCT068627392 locations